- Home
- EYPT vs GRC Comparison
EYPT vs GRC Comparison
Compare EYPT & GRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | GRC |
|---|---|---|
| Founded | 1987 | 1933 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Fluid Controls |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | EYPT | GRC |
|---|---|---|
| Price | $16.21 | $51.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $28.75 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 90.5K |
| Earning Date | 11-05-2025 | 02-06-2026 |
| Dividend Yield | N/A | ★ 1.49% |
| EPS Growth | N/A | ★ 31.51 |
| EPS | N/A | ★ 1.91 |
| Revenue | $42,339,000.00 | ★ $678,522,000.00 |
| Revenue This Year | N/A | $4.94 |
| Revenue Next Year | N/A | $4.02 |
| P/E Ratio | ★ N/A | $26.62 |
| Revenue Growth | N/A | ★ 3.19 |
| 52 Week Low | $3.91 | $30.87 |
| 52 Week High | $19.11 | $52.02 |
Technical Indicators
Market Signals| Indicator | EYPT | GRC |
|---|---|---|
| Relative Strength Index (RSI) | 46.35 | 62.60 |
| Support Level | $16.67 | $47.33 |
| Resistance Level | $18.20 | $49.87 |
| Average True Range (ATR) | 1.01 | 1.16 |
| MACD | -0.31 | 0.02 |
| Stochastic Oscillator | 3.56 | 85.65 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About GRC Gorman-Rupp Company (The)
Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of revenue from the United States.